Discovery of Neurolysin Activators with Preclinical Efficacy in an Ischemic Stroke Model
Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 26057-26077
DOI: 10.1021/acs.jmedchem.6c02108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.10.2026. Verfasst von Shikha Kumari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska68106, USA. Hauptthemen laut MEDLINE: Neuroprotective Agents, Ischemic Stroke, Metalloendopeptidases, Drug Discovery. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Oakland University William Beaumont School of Medicine, University of Nebraska Medical Center, Texas Tech University Health Sciences Center.
Themen: Schlaganfall
Abstract (Originalsprache)
The peptidase neurolysin (Nln) is upregulated following ischemic stroke to activate endogenous cerebroprotective mechanisms and has subsequently emerged as a therapeutic target for drug discovery efforts. Overexpression of Nln in a mouse model of ischemic stroke results in significant improvement of stroke outcomes. Herein, we report the discovery of the first non-peptide Nln activators based around a central pyridine-piperazine scaffold that possesses nanomolar potency. This scaffold, exemplified by compounds 7c and 7g, exhibits greater in vitro half-life, blood−brain barrier penetration, mouse brain and mouse plasma stability than previously reported peptidomimetic Nln activators. Compound 7g afforded an in vivo protective effect in the MCAO mouse model of ischemic stroke, significantly reducing infarct volume and brain water content, marking the first report of a small molecule Nln activator with in vivo cerebroprotective effects in a preclinical model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska68106, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas79106, USA.
- Department of Foundational Medical Studies, William Beaumont School of Medicine, Oakland University, Rochester, Michigan48309, USA.
- Brain Drug Discovery Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas79105, United States.
- Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska68106, USA.
- UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska68106, USA.
ORCID-Profile: Shirisha Jonnalagadda, Vardan T Karamyan, Paul C Trippier
Förderung
- Oakland University William Beaumont School of Medicine
- University of Nebraska Medical Center
- Texas Tech University Health Sciences Center
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Kumari, S., Maddeboina, K., Esfahani, S. H., Jonnalagadda, S., Hao, X., Queen, A., Zhang, Y., Aly, A., Kandil, H., Nozohouri, S., Elaraky, H., Abbruscato, T. J., Karamyan, V. T., & Trippier, P. C. (2026). Discovery of Neurolysin Activators with Preclinical Efficacy in an Ischemic Stroke Model. Journal of Medicinal Chemistry, 69(21), 26057-26077. https://doi.org/10.1021/acs.jmedchem.6c02108
Vancouver
Kumari S, Maddeboina K, Esfahani SH, Jonnalagadda S, Hao X, Queen A, et al. Discovery of Neurolysin Activators with Preclinical Efficacy in an Ischemic Stroke Model. Journal of Medicinal Chemistry. 2026;69(21):26057-26077. doi:10.1021/acs.jmedchem.6c02108
BibTeX
@article{Kumari2026,
author = {Kumari, Shikha and Maddeboina, Krishnaiah and Esfahani, Shiva Hadi and Jonnalagadda, Shirisha and Hao, Xiaoyu and Queen, Aarfa and Zhang, Yong and Aly, Asmaa and Kandil, Haya and Nozohouri, Saeideh and Elaraky, Hossam and Abbruscato, Thomas J and Karamyan, Vardan T and Trippier, Paul C},
title = {Discovery of Neurolysin Activators with Preclinical Efficacy in an Ischemic Stroke Model},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {21},
pages = {26057--26077},
doi = {10.1021/acs.jmedchem.6c02108}
}
EUVIMED